TABLE 2.
Secondary end points
| Secondary end point | Control group | OPAT group | P |
|---|---|---|---|
| Patients with reported adverse drug reactions, n (%) | 5 (23.8) | 5 (23.8) | 0.72 |
| Allergic reaction | 2 | 1 | |
| Hematological | 0 | 1 | |
| Renal/liver toxicity | 1 | 1 | |
| Gastrointestinal | 0 | 1 | |
| Neurological | 1 | 0 | |
| Abnormal drug level | 0 | 2 | |
| Other | 1 | 0 | |
| Total reported adverse drug reactions | 5 | 6 | |
| Patients with therapy stopped/switched due to ADR, n (%) | 3 (60.0) | 1 (20.0) | 0.62 |
| VAD-related complications, n (%) | 2 (9.5) | 2 (9.5) | 0.62 |
Data presented as n unless otherwise specified. ADR Adverse drug reaction; OPAT Outpatient parenteral antimicrobial therapy; VAD Vascular access device